Long‐Term Antiarrhythmic Therapy With Cibenzoline

Syed M. Mohiuddin, Daniel E. Hilleman, Dennis Esterbrooks, Aryan N. Mooss, Lois A. Stengel

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

This single-blind, placebo-controlled study evaluated long-term therapy with cibenzoline in 19 patients with chronic ventricular arrhythmias. Antiarrhythmic efficacy, defined as ≥75% reduction in single premature ventricular complexes (PVCs), ≥90% reduction in paired PVCs, and total abolition of ventricular tachycardia (VT), was established after dose titration in 14 of 19 (74%) patients. Mean frequency of single PVCs was reduced by 65%, mean paired PVC frequency was reduced by 68%, and mean VT event frequency was reduced by 82%. Antiarrhythmic efficacy was maintained during long-term therapy in five of the 14 (36%) short-term responders. Of the nine patients who discontinued cibenzoline during long-term follow-up, five had a loss of arrhythmia control, three failed to redevelop arrhythmias during placebo reintroduction, and one developed an adverse reaction. Three patients (16%) experienced a proarrhythmic effect. Echocardiographic evaluation did not reveal any deleterious effect of cibenzoline on left ventricular function in the group as a whole. In six patients with preexisting left ventricular dysfunction, left ventricular ejection fraction and fractional shortening improved significantly (P

Original languageEnglish (US)
Pages (from-to)400-406
Number of pages7
JournalThe Journal of Clinical Pharmacology
Volume27
Issue number5
DOIs
StatePublished - Jan 1 1987

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this